CRL Charles River Laboratories International, Inc. Common Stock
$288,77
Precio · Ago 18, 2026
Fundamentales a fecha de Ago 5, 2026
Rango 52S
$144–$289
100% of range
Calificación del Analista
BUY
22 analysts
Precio Objetivo
$281
P/E (TTM)
-99.2
ROE
-4.4%
Margen de Beneficio Neto
-3.6%
Acerca de Charles River Laboratories International, Inc. Common Stock Descripción general de la empresa de Wikipedia
Charles River Laboratories International, Inc. is an American pharmaceutical and biotechnology contract research organisation (CRO) headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides preclinical and clinical laboratory services for the development of new drugs, vaccines, and medical devices. Its operations span at least 20 countries, offering research models, safety assessment, and manufacturing support services to pharmaceutical, biotechnology, and government clients.
Leer más
Charles River Laboratories International, Inc. is an American pharmaceutical and biotechnology contract research organisation (CRO) headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides preclinical and clinical laboratory services for the development of new drugs, vaccines, and medical devices. Its operations span at least 20 countries, offering research models, safety assessment, and manufacturing support services to pharmaceutical, biotechnology, and government clients.
Charles River Laboratories is considered one of the largest CROs globally, known for its role in toxicology studies, animal research models, and microbial testing services used in regulatory submissions to health authorities such as the U.S. Food and Drug Administration (FDA). The company has also been the subject of public scrutiny and regulatory attention over its use of laboratory animals, including dogs, primates, and horseshoe crabs.
As of 2024, the company employs over 20,000 people worldwide and is publicly traded on the New York Stock Exchange under the ticker symbol CRL.
History
Charles River was founded in 1947 by Henry Foster, a young veterinarian who purchased one thousand rat cages from a Virginia farm and set up a one-person laboratory in Boston overlooking the Charles River. He supplied local researchers with laboratory animals.
In 1955, the company's headquarters were relocated to their current home in Wilmington, Massachusetts. The organization became an international entity in 1966 by opening a new animal production facility in France.
The first commercial, comprehensive genetic monitoring program was implemented by Charles River in 1981. Three years later, they were acquired by Bausch & Lomb. In 1988, the organization began creating transgenic mice and rats. In the 1990s, they began in vitro endotoxin testing. In the 1990s, Jim Foster bought Charles River back from Bausch & Lomb, and the company later went public on the New York Stock Exchange.
Charles River launched the Humane Care Imperative in 2002, designed to raise awareness and train employees on animal welfare's importance. The same year, they were named "Company of the Year" by The Boston Globe. The company introduced preconditioning services in 2005 to provide customers with study-ready animals.
In 2008, Charles River signed a ten-year contract to partner with the National Cancer Institute and opened a facility in Frederick, Maryland.
In April 2019, Charles River announced it would cease its San Diego operations, moving the breeding of rodents for testing compounds to Hollister, California.
In March 2023, the Born Free USA animal welfare organization protested against Charles River's plan to export 1,000 endangered juvenile long-tail macaques to Cambodia for testing.
Acquisitions
In 1988, Charles River purchased Specific Pathogen Antigen Free Avian Services (SPAFAS) and serologic diagnostic services Merck, Sharp, and Dohme.
Between 1996 and 2000, the company acquired Endosafe, Inc. and Sierra Biomedical.
In October 2003, Charles River Laboratories merged with Inveresk, a research company based in the United Kingdom. The company was known then as Charles River Laboratories. Inveresk specialised in clinical research and pre-clinical testing, and their main facilities are in Edinburgh, Scotland. In late 2009, Charles River sold its Clinical Services Division in Edinburgh to Quotient Bioresearch.
In 2010, Charles River Laboratories attempted to acquire WuXi PharmaTech, a China-based contract research organization, but the offer was withdrawn when the deal faced opposition from several large Charles River investors, including Relational Investors, JANA Partners, and Neuberger Berman. The proxy advisory firm RiskMetrics had also recommended that Charles River's shareholders vote against the proposed deal.
From 2008 to 2013, Charles River acquires several companies including NewLab Bioquality AG, MIR Preclinical Services, Piedmont Research Center, LLC, Cerebricon, Ltd., Accugenix, and Vital River, allowing the company to expand their research models and services portfolio to drug development and discovery markets in China.
The acquisitions of Argenta and BioFocus in 2014 allowed Charles River to establish itself as a full-service, early-stage contract research organization with integrated in vitro and in vivo capabilities from target discovery through pre-clinical development.
In July 2015, the company announced it would acquire Celsis International for $212 million.
In 2016, the company announced it was set to acquire WIL Research for approximately $585 million in cash and Blue Stream Laboratories.
In August 2017, the business announced it would acquire Brains On-Line.
In January 2018, the company announced it would acquire KWS BioTest for up to £18 million ($24.4 million). In February of the same year, Charles River announced it would acquire MPI Research for approximately $800 million in cash. The transaction was completed on April 3, 2018.
In February 2019, the company announced it would acquire Citoxlab for €448 million in cash (approximately $500 million), including the former acquisitions of the French company, AccelLAB, Atlanbio and Solvo Biotechnology. The transaction was completed on April 29. In December of the same year the business announced it would acquire HemaCare for approximately $380 million in cash.
In August 2020, the company announced it would acquire Cellero for $38 million in cash.
In January 2021, the company announced it would acquire Distributed Bio, Inc., an antibody discovery business.
In February 2021, Charles River announced it would acquire Cognate BioServices, Inc. for $875 million.
In March 2021, Charles River announced the acquisition of Retrogenix for $48 million.
In May 2021, Charles River announced the acquisition of Vigene Biosciences, a gene therapy contract development and manufacturing organization (CDMO), for $292.5 million.
In October 2021, a Japanese subsidiary of Charles River was acquired by Jackson Laboratory for $63M USD.
In April 2022, the company announced it would acquire Explora BioLabs.
In January 2023, the business announced it would acquire SAMDI Tech, Inc.
Fuente: Wikipedia (Inglés), CC BY-SA 4.0 · Ver en Wikipedia ↗
CRL Instantánea de la Acción Precio, capitalización bursátil, P/E, BPA, ROE, deuda/capital, rango de 52 semanas
Precio
$288.77
Capitalización Bursátil
$14.21B
P/E (TTM)
-99.2
BPA (TTM)
$-2.91
Ingresos (TTM)
$4.02B
Rendimiento div.
—
ROE
-4.4%
Deuda/Capital
0.0
Rango 52S
$144 – $289
CRL Gráfico del Precio de la Acción OHLCV diario con indicadores técnicos — desplace, amplíe y personalice su vista
Configure
Rendimiento a 10 años Tendencias de ingresos, beneficio neto, márgenes y BPA
Ingresos y Beneficio Neto
$4.02B
2016-12-31
→
2025-12-27
BPA
$-2.91
2016-12-31
→
2025-12-27
Flujo de caja libre
$518M
2016-12-31
→
2025-12-27
Márgenes
-3.6%
Valoración Ratios P/E, P/S, P/B, EV/EBITDA: ¿está la acción cara o barata?
Métrica
Tendencia a 5 años
CRL
Mediana de Pares
P/E (TTM)
-99.2
39.9
P/S (TTM) (P/V (TTM))
3.5
5.6
P/B (P/C)
4.5
4.1
EV / EBITDA
32.7
—
Price / FCF (Precio / FCF)
27.4
—
Rentabilidad Márgenes brutos, operativos y netos; ROE, ROA, ROIC
Métrica
Tendencia a 5 años
CRL
Mediana de Pares
Operating Margin (Margen Operativo)
0.63%
—
Net Profit Margin (Margen de Beneficio Neto)
-3.6%
11.7%
ROA
-2.0%
4.7%
ROE
-4.4%
8.5%
ROIC
1.1%
—
Salud financiera Deuda, liquidez, solvencia — solidez del balance general
Métrica
Tendencia a 5 años
CRL
Mediana de Pares
Debt / Equity (Deuda / Patrimonio)
0.0
15.3
Current Ratio (Ratio corriente)
1.3
1.7
Quick Ratio (Ratio Rápido)
0.8
—
Crecimiento Crecimiento de ingresos, BPA y beneficio neto: interanual, CAGR a 3 años, CAGR a 5 años
Métrica
Tendencia a 5 años
CRL
Mediana de Pares
Revenue YoY (Ingresos interanuales)
-0.85%
—
Revenue CAGR 3Y (Ingresos CAGR 3A)
0.33%
—
Revenue CAGR 5Y (Ingresos CAGR 5A)
6.6%
—
EPS YoY (EPS interanual)
-97.8%
—
Net Income YoY (Beneficio Neto interanual)
-95.3%
—
Eficiencia de capital Rotación de activos, rotación de inventario, rotación de cuentas por cobrar
Métrica
Tendencia a 5 años
CRL
Mediana de Pares
CRL Consenso de analistas Opiniones de analistas alcistas y bajistas, precio objetivo a 12 meses, potencial alcista
COMPRA
22 analistas
- Compra fuerte 5 22,7%
- Compra 10 45,5%
- Mantener 7 31,8%
- Venta 0 0,0%
- Venta fuerte 0 0,0%
Precio objetivo a 12 meses
14 analistas · 2026-08-14
Mediana
$300.00
Media
$281.00
Ahora
$288.77
Mín
$145.00
Máx
$318.00
Objetivo mediano
$300.00
+3,9%
Objetivo medio
$281.00
-2,7%
Historial de Ganancias EPS real vs estimado, sorpresa %, tasa de aciertos, próxima fecha de resultados
Sorpresa Media
0.21%
| Período | EPS Actual | EPS est. | Sorpresa |
|---|---|---|---|
| 30 de junio de 2026 | $3.02 | $2.76 | 0.26% |
| 31 de marzo de 2026 | $2.06 | $1.96 | 0.10% |
| 31 de diciembre de 2025 | $2.39 | $2.37 | 0.02% |
| 30 de septiembre de 2025 | $2.43 | $2.36 | 0.07% |
| 30 de junio de 2025 | $3.12 | $2.52 | 0.60% |
| 31 de marzo de 2025 | $2.34 | $2.10 | 0.24% |
Comparación de pares (subindustria GICS) Métricas clave frente a competidores del sector
| Ticker | Capitalización Bursátil | P/E | Ingresos interanuales | Margen Neto | ROE | Margen Bruto |
|---|---|---|---|---|---|---|
| CRL | $10.02B | -70.0 | -0.85% | -3.6% | -4.4% | — |
| ILMN | $20.65B | 24.8 | -0.66% | 19.6% | 34.1% | 66.1% |
| MTD | $28.38B | 33.2 | 4.0% | 21.6% | -615.5% | 59.4% |
| WST | $19.81B | 40.5 | 6.2% | 16.1% | 16.2% | 35.9% |
| MEDP | $15.93B | 36.8 | 20.0% | 17.8% | 142.9% | — |
| TEM | — | -41.9 | 83.4% | -19.3% | -61.2% | — |
| RVTY | $10.86B | 46.7 | 3.7% | 8.5% | 3.3% | — |
| TECH | $7.97B | 111.8 | 5.2% | 6.0% | 3.7% | 64.8% |
| BIO | — | — | — | — | — | — |
| RGEN | $9.23B | 190.5 | 16.4% | 6.6% | 2.4% | — |
| TEM | — | -41.9 | 83.4% | -19.3% | -61.2% | — |
Fundamentales Completos Todas las métricas por año — estado de resultados, balance general, flujo de caja
Estado de resultados 15
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.02B | $4.05B | $4.13B | $3.98B | $3.54B | $2.92B | $2.62B | $2.27B | $1.86B | $1.68B | $1.36B | $1.30B | |
| Cost of Revenue | · | · | · | · | · | · | · | · | $290M | $277M | $264M | $266M | |
| SG&A Expense | $743M | $751M | $748M | $665M | $620M | $529M | $518M | $444M | $371M | $365M | $300M | $269M | |
| Operating Income | $25M | $227M | $617M | $651M | $590M | $433M | $351M | $331M | $288M | $238M | $206M | $178M | |
| Interest Expense | · | · | $137M | $59M | $74M | $86M | $61M | $64M | $30M | $28M | $15M | $12M | |
| Interest Income | $5M | $9M | $5M | $780.0K | $652.0K | $834.0K | $2M | $812.0K | $690.0K | $1M | $1M | $1M | |
| Other Non-op | $-23M | $-17M | $96M | $31M | $-36M | $100M | $12M | $13M | $38M | $12M | $3M | $11M | |
| Pretax Income | $-100M | $93M | $581M | $623M | $481M | $447M | $304M | $282M | $297M | $223M | $195M | $178M | |
| Income Tax | $43M | $68M | $101M | $130M | $82M | $82M | $50M | $54M | $171M | $67M | $43M | $48M | |
| Net Income | $-144M | $22M | $475M | $486M | $391M | $364M | $252M | $226M | $123M | $155M | $149M | $127M | |
| EPS (Basic) | $-2.91 | $0.20 | $9.27 | $9.57 | $7.77 | $7.35 | $5.17 | $4.72 | $2.60 | $3.29 | $3.21 | $2.72 | |
| EPS (Diluted) | $-2.91 | $0.20 | $9.22 | $9.48 | $7.60 | $7.20 | $5.07 | $4.62 | $2.54 | $3.23 | $3.13 | $2.66 | |
| Shares (Basic) | 49,564,000 | 51,380,000 | 51,227,000 | 50,812,000 | 50,293,000 | 49,550,000 | 48,730,000 | 47,947,000 | 47,481,000 | 47,014,000 | 46,496,000 | 46,627,000 | |
| Shares (Diluted) | 49,564,000 | 51,628,000 | 51,451,000 | 51,301,000 | 51,425,000 | 50,611,000 | 49,693,000 | 49,018,000 | 48,564,000 | 47,958,000 | 47,634,000 | 47,558,000 | |
| EBITDA | $428M | $589M | $931M | $955M | $855M | $668M | $549M | $493M | $419M | $364M | $301M | $274M |
Balance general 30
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $214M | $195M | $277M | $234M | $241M | $228M | $238M | $195M | $164M | $118M | $118M | $160M | |
| Short-term Investments | · | · | · | · | $1M | $1M | $941.0K | $885.0K | $28M | $4M | $21M | · | |
| Receivables | $709M | $721M | $780M | $752M | $643M | $618M | $514M | $472M | $430M | $364M | $270M | $258M | |
| Inventory | $299M | $279M | $380M | $256M | $199M | $186M | $161M | $128M | $115M | $96M | $94M | $89M | |
| Prepaid Expense | $129M | $106M | $83M | $108M | $97M | $73M | $56M | $49M | $81M | $45M | $47M | $45M | |
| Other Current Assets | · | · | · | · | · | $0 | $300.0K | $300.0K | $0 | $45M | $47M | $73M | |
| Current Assets | $1.45B | $1.40B | $1.61B | $1.44B | $1.27B | $1.20B | $1.02B | $898M | $827M | $657M | $559M | $579M | |
| PP&E (Net) | $1.66B | $1.60B | $1.64B | $1.47B | $1.29B | $1.12B | $1.04B | $933M | $782M | $756M | $678M | $677M | |
| PP&E (Gross) | $3.19B | $3.06B | $2.98B | $2.63B | $2.39B | $2.21B | $2.02B | $1.81B | $1.58B | $1.46B | $1.32B | $1.33B | |
| Accum. Depreciation | $1.54B | $1.45B | $1.34B | $1.16B | $1.10B | $1.09B | $978M | $874M | $801M | $706M | $645M | $655M | |
| Goodwill | $2.76B | $2.85B | $3.10B | $2.85B | $2.71B | $1.81B | $1.54B | $1.25B | $805M | $788M | $439M | $321M | |
| Intangibles | $340M | $723M | $864M | $955M | $1.06B | $788M | $689M | $611M | $370M | $394M | $281M | $281M | |
| Other Non-current Assets | $293M | $278M | $309M | $148M | $152M | $353M | $213M | $144M | $124M | $88M | $72M | $73M | |
| Total Assets | $7.14B | $7.53B | $8.20B | $7.60B | $7.02B | $5.49B | $4.69B | $3.86B | $2.93B | $2.71B | $2.07B | $1.87B | |
| Accounts Payable | $149M | $140M | $169M | $206M | $198M | $122M | $111M | $66M | $78M | $68M | $37M | $34M | |
| Accrued Liabilities | $270M | $232M | $228M | $220M | $229M | $150M | $139M | $107M | $90M | $84M | $89M | $67M | |
| Current Liabilities | $1.12B | $994M | $1.06B | $1.09B | $1.03B | $840M | $710M | $558M | $464M | $430M | $312M | $295M | |
| Capital Leases | $434M | $484M | $419M | $390M | $253M | $156M | $116M | · | · | · | · | · | |
| Deferred Tax | $95M | $107M | $191M | $216M | $240M | $217M | $167M | $144M | $90M | $56M | $48M | $23M | |
| Other Non-current Liabilities | $138M | $195M | $223M | $175M | $243M | $205M | $183M | $179M | $195M | $159M | $89M | $100M | |
| Total Liabilities | $3.92B | $4.02B | $4.54B | $4.58B | $4.43B | $3.35B | $3.03B | $2.52B | $1.87B | $1.86B | $1.30B | $1.17B | |
| Long-term Debt | · | · | · | · | · | · | · | $1.61B | $1.09B | $1.18B | $814M | $717M | |
| Total Debt | $166.0K | $155.0K | $3M | $1M | $101.0K | $47M | $36M | $1.65B | $1.12B | $1.21B | $836M | $754M | |
| Common Stock | $492.0K | $511.0K | $513.0K | $509.0K | $505.0K | $498.0K | $489.0K | $482.0K | $875.0K | $863.0K | $855.0K | $845.0K | |
| Retained Earnings | $1.39B | $1.81B | $1.89B | $1.43B | $981M | $625M | $280M | $42M | $289M | $165M | $11M | $-139M | |
| Treasury Stock | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $55.0K | $1.66B | $1.55B | $1.54B | $1.42B | |
| AOCI | $-172M | $-317M | $-196M | $-262M | $-165M | $-139M | $-178M | $-173M | $-145M | $-254M | $-136M | $-74M | |
| Stockholders' Equity | $3.16B | $3.46B | $3.60B | $2.98B | $2.53B | $2.11B | $1.63B | $1.32B | $1.05B | $837M | $733M | $672M | |
| Liabilities + Equity | $7.14B | $7.53B | $8.20B | $7.60B | $7.02B | $5.49B | $4.69B | $3.86B | $2.93B | $2.71B | $2.07B | $1.87B | |
| Shares Outstanding | 49,217,000 | 51,141,000 | 51,338,000 | 50,944,000 | 50,480,000 | 49,767,000 | 48,936,000 | 48,209,000 | 47,402,000 | 47,363,000 | 46,698,000 | 47,327,000 |
Flujo de Efectivo 18
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $403M | $362M | $314M | $304M | $266M | $235M | $198M | $162M | $131M | $127M | $95M | $96M | |
| Stock-based Comp | $71M | $70M | $72M | $74M | $71M | $56M | $57M | $47M | $44M | $44M | $40M | $31M | |
| Deferred Tax | $-75M | $-67M | $-51M | $-33M | $-20M | $2M | $-21M | $-10M | $28M | $3M | $4M | $9M | |
| Amort. of Intangibles | $179M | $138M | $137M | $147M | $125M | $112M | $90M | $65M | $41M | $42M | $24M | $26M | |
| Restructuring | $100M | $107M | $30M | $8M | $7M | $13M | $14M | $10M | $5M | $18M | $8M | $8M | |
| Other Non-cash | $483M | $348M | $-126M | $-211M | $53M | $-111M | $-5M | $16M | $-8M | $-28M | $-395.0K | · | |
| Operating Cash Flow | $738M | $735M | $684M | $620M | $761M | $547M | $481M | $441M | $318M | $317M | $307M | $252M | |
| CapEx | $219M | $233M | $319M | $325M | $229M | $167M | $141M | $140M | $82M | $55M | $63M | $57M | |
| Investing Cash Flow | $-209M | $-245M | $-563M | $-608M | $-1.44B | $-602M | $-682M | $-955M | $-73M | $-693M | · | · | |
| Debt Issued | $1.23B | $1.08B | $776M | $2.95B | $6.95B | $2.23B | $3.36B | $2.76B | $237M | $1.04B | · | · | |
| Net Debt Issued | $1.23B | $1.08B | $776M | $2.95B | $6.95B | $2.23B | $3.36B | $2.76B | · | · | · | · | |
| Stock Repurchased | $361M | $119M | $24M | $39M | $41M | $24M | $18M | $14M | $107M | $12M | $117M | $122M | |
| Net Stock Activity | $-361M | $-119M | $-24M | $-39M | $-41M | $-24M | $-18M | $-14M | $-107M | $-12M | $-117M | $-122M | |
| Financing Cash Flow | $-537M | $-551M | $-86M | $-42M | $673M | $47M | $232M | $558M | $-208M | $381M | · | · | |
| Net Change in Cash | $10M | $-79M | $43M | $-5M | $13M | $-7M | $43M | $31M | $46M | $-69.0K | $-43M | $4M | |
| Taxes Paid | $120M | $126M | $90M | $76M | $75M | $60M | $54M | $68M | · | · | · | · | |
| Free Cash Flow | $518M | $502M | $365M | $295M | $532M | $380M | $340M | $301M | $236M | $245M | $225M | $195M | |
| Levered FCF | · | · | $252M | $248M | $471M | $309M | $290M | $250M | $223M | $226M | $213M | $186M |
Rentabilidad 7
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 0.63% | 5.6% | 14.9% | 16.4% | 16.7% | 14.8% | 13.4% | 14.6% | 15.5% | 14.1% | 15.1% | 13.7% | |
| Net Margin | -3.6% | 0.55% | 11.5% | 12.2% | 11.0% | 12.5% | 9.6% | 10.0% | 6.6% | 9.2% | 10.9% | · | |
| Pretax Margin | -2.5% | 2.3% | 14.1% | 15.7% | 13.6% | 15.3% | 11.6% | 12.4% | 16.0% | 13.3% | 14.3% | 13.7% | |
| EBITDA Margin | 10.7% | 14.5% | 22.6% | 24.0% | 24.2% | 22.8% | 20.9% | 21.8% | 22.5% | 21.6% | 22.1% | 21.1% | |
| ROA | -2.0% | 0.28% | 6.0% | 6.7% | 6.2% | 7.1% | 5.9% | 6.7% | 4.4% | 6.5% | 7.6% | · | |
| ROE | -4.4% | 0.63% | 14.4% | 17.6% | 16.8% | 19.4% | 17.1% | 19.2% | 13.1% | 19.7% | 21.2% | · | |
| ROIC | 1.1% | 1.8% | 14.2% | 17.3% | 19.3% | 16.4% | 17.6% | 9.0% | 5.6% | 8.1% | 10.2% | 9.1% |
Liquidez y Solvencia 5
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.3 | 1.4 | 1.5 | 1.3 | 1.2 | 1.4 | 1.4 | 1.6 | 1.8 | 1.5 | 1.8 | 2.0 | |
| Quick Ratio | 0.8 | 0.9 | 1.0 | 0.9 | 0.9 | 1.0 | 1.1 | 1.2 | 1.3 | 1.1 | 1.2 | 1.4 | |
| Debt / Equity | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.3 | 1.1 | 1.4 | 1.1 | 1.1 | |
| LT Debt / Equity | · | · | · | · | · | · | · | 1.2 | 1.0 | 1.4 | 1.1 | 1.1 | |
| Interest Coverage | · | · | 4.5 | 11.0 | 8.0 | 5.0 | 5.8 | 5.2 | 9.7 | 8.6 | 13.7 | 14.9 |
Eficiencia 3
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.5 | 0.5 | 0.5 | 0.5 | 0.6 | 0.6 | 0.6 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | |
| Inventory Turnover | · | · | · | · | · | · | · | · | 2.7 | 2.9 | 2.9 | 3.0 | |
| Receivables Turnover | 5.6 | 5.4 | 5.4 | 5.7 | 5.6 | 5.2 | 5.3 | 5.0 | 4.7 | 5.3 | 5.2 | 5.4 |
Tasas de Crecimiento 7
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -0.85% | -1.9% | 3.9% | 12.3% | 21.1% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 0.33% | 4.6% | 12.2% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 6.6% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | · | -97.8% | -2.7% | 24.7% | 5.6% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | · | -70.3% | 8.6% | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | · | -95.3% | -2.4% | 24.4% | 7.3% | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | · | -61.6% | 9.2% | · | · | · | · | · | · | · | · | · |
Valoración (TTM) 14
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $4.02B | $4.05B | $4.13B | $3.98B | $3.54B | $2.92B | $2.62B | $2.27B | $1.86B | $1.68B | $1.36B | $1.30B | |
| Net Income TTM | $-144M | $22M | $475M | $486M | $391M | $364M | $252M | $226M | $123M | $155M | $149M | $127M | |
| Market Cap | $10.02B | $9.52B | $12.14B | $11.10B | $18.64B | $12.53B | $7.43B | $5.39B | $5.19B | $3.61B | $3.74B | $3.04B | |
| Enterprise Value | $9.81B | $9.33B | $11.86B | $10.87B | $18.40B | $12.34B | $7.23B | $6.84B | $6.12B | $4.70B | $4.46B | $3.64B | |
| P/E | -70.0 | 930.8 | 25.6 | 23.0 | 48.6 | 35.0 | 30.0 | 24.2 | 43.1 | 23.6 | 25.6 | 24.2 | |
| P/S | 2.5 | 2.4 | 2.9 | 2.8 | 5.3 | 4.3 | 2.8 | 2.4 | 2.8 | 2.1 | 2.7 | 2.3 | |
| P/B | 3.2 | 2.8 | 3.4 | 3.7 | 7.4 | 5.9 | 4.5 | 4.1 | 5.0 | 4.3 | 5.1 | 4.5 | |
| P / Tangible Book | 166.0 | · | · | · | · | · | · | · | · | · | · | · | |
| P / Cash Flow | 13.6 | 13.0 | 17.7 | 17.9 | 24.5 | 22.9 | 15.5 | 12.2 | 16.3 | 12.0 | 13.0 | 12.1 | |
| P / FCF | 19.3 | 19.0 | 33.2 | 37.6 | 35.0 | 33.0 | 21.8 | 17.9 | 22.0 | 14.7 | 16.6 | 15.6 | |
| EV / EBITDA | 22.9 | 15.8 | 12.7 | 11.4 | 21.5 | 18.5 | 13.2 | 13.9 | 14.6 | 12.9 | 14.8 | 13.3 | |
| EV / FCF | 18.9 | 18.6 | 32.5 | 36.9 | 34.6 | 32.5 | 21.2 | 22.7 | 26.0 | 19.2 | 19.8 | 18.6 | |
| EV / Revenue | 2.4 | 2.3 | 2.9 | 2.7 | 5.2 | 4.2 | 2.8 | 3.0 | 3.3 | 2.8 | 3.3 | 2.8 | |
| Earnings Yield | -1.4% | 0.11% | 3.9% | 4.3% | 2.1% | 2.9% | 3.3% | 4.1% | 2.3% | 4.2% | 3.9% | 4.1% |
Estado de resultados 14
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.00B | $996M | $994M | $1.00B | $1.03B | $984M | $1.00B | $1.01B | $1.03B | $1.01B | $1.01B | $1.03B | $1.03B | $1.10B | $989M | |
| Cost of Revenue | · | · | · | · | · | · | · | $661M | $672M | $667M | · | $665M | $652M | · | · | |
| SG&A Expense | $229M | $159M | $196M | $178M | $192M | $178M | $196M | $199M | $170M | $186M | $197M | $176M | $175M | $200M | $184M | |
| Operating Income | $120M | $120M | $-283M | $134M | $100M | $75M | $-168M | $117M | $152M | $126M | $133M | $152M | $168M | $164M | $151M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $35M | · | $34M | $34M | · | $11M | |
| Interest Income | $1M | $1M | $1M | $1M | $1M | $1M | $2M | $2M | $3M | $2M | $2M | $1M | $806.0K | $343.0K | $122.0K | |
| Other Non-op | $-37M | $-124M | $12M | $-23M | $154.0K | $-12M | $-23M | $3M | $-2M | $6M | $108M | $-6M | $-3M | $116M | $-17M | |
| Income Tax | $54M | $-15M | $-18M | $32M | $19M | $10M | $-3M | $21M | $25M | $25M | $20M | $25M | $27M | $56M | $25M | |
| Net Income | $-1M | $-15M | $-277M | $54M | $52M | $25M | $-214M | $70M | $94M | $73M | $187M | $87M | $103M | $187M | $96M | |
| EPS (Basic) | $-0.03 | $-0.30 | $-5.58 | $1.11 | $1.06 | $0.50 | $-4.20 | $1.34 | $1.75 | $1.31 | $3.65 | $1.70 | $2.02 | $3.68 | $1.90 | |
| EPS (Diluted) | $-0.03 | $-0.30 | $-5.57 | $1.10 | $1.06 | $0.50 | $-4.17 | $1.33 | $1.74 | $1.30 | $3.64 | $1.69 | $2.01 | $3.66 | $1.88 | |
| Shares (Basic) | 48,021,000 | 48,951,000 | -99,475,000 | 49,213,000 | 49,149,000 | 50,677,000 | -103,002,000 | 51,394,000 | 51,551,000 | 51,437,000 | 28,000 | 51,283,000 | 51,097,000 | -101,521,000 | 50,870,000 | |
| Shares (Diluted) | 48,021,000 | 48,951,000 | -100,031,000 | 49,426,000 | 49,316,000 | 50,853,000 | -103,643,000 | 51,583,000 | 51,846,000 | 51,842,000 | -42,000 | 51,607,000 | 51,428,000 | -102,590,000 | 51,283,000 | |
| EBITDA | $187M | $187M | · | $219M | $220M | $195M | · | $206M | $238M | $211M | · | $230M | $245M | · | $226M |
Balance general 28
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $192M | $192M | $214M | $207M | $183M | $229M | $195M | $210M | $179M | $327M | · | $157M | $202M | · | $194M | |
| Short-term Investments | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $950.0K | |
| Receivables | $712M | $700M | $709M | $734M | $768M | $757M | $721M | $754M | $762M | $787M | · | $799M | $788M | · | $771M | |
| Inventory | $346M | $360M | $299M | $303M | $280M | $290M | $279M | $336M | $349M | $361M | · | $293M | $263M | · | $262M | |
| Prepaid Expense | $179M | $135M | $129M | $166M | $130M | $100M | $106M | $102M | $111M | $99M | · | $93M | $92M | · | $97M | |
| Current Assets | $1.53B | $1.49B | $1.45B | $1.53B | $1.47B | $1.51B | $1.40B | $1.49B | $1.50B | $1.67B | · | $1.44B | $1.45B | · | $1.42B | |
| PP&E (Net) | $1.49B | $1.51B | $1.66B | $1.59B | $1.61B | $1.59B | $1.60B | · | · | · | · | · | · | · | · | |
| PP&E (Gross) | $2.96B | $2.94B | $3.19B | $3.09B | $3.10B | $3.05B | $3.06B | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | $1.46B | $1.43B | $1.54B | $1.50B | $1.50B | $1.46B | $1.45B | · | · | · | · | · | · | · | · | |
| Goodwill | $3.08B | $3.04B | $2.76B | $2.92B | $2.94B | $2.87B | $2.85B | $3.12B | $3.08B | $3.07B | · | $2.88B | $2.90B | · | $2.78B | |
| Intangibles | $253M | $249M | $340M | $571M | $602M | $656M | $723M | $778M | $800M | $828M | · | $886M | $958M | · | $968M | |
| Other Non-current Assets | $588M | $826M | $293M | $291M | $296M | $294M | $278M | $307M | $301M | $303M | · | $155M | $154M | · | $430M | |
| Total Assets | $7.53B | $7.73B | $7.14B | $7.51B | $7.56B | $7.58B | $7.53B | $8.00B | $7.95B | $8.15B | · | $7.61B | $7.70B | · | $7.38B | |
| Accounts Payable | $141M | $134M | $149M | $170M | $146M | $149M | $140M | $136M | $133M | $130M | · | $136M | $120M | · | $182M | |
| Accrued Liabilities | $380M | $372M | $270M | $229M | $232M | $242M | $232M | $208M | $192M | $191M | · | $198M | $221M | · | $197M | |
| Current Liabilities | $1.13B | $1.09B | $1.12B | $1.12B | $1.08B | $1.05B | $994M | $1.01B | $948M | $955M | · | $994M | $981M | · | $1.01B | |
| Capital Leases | $408M | $393M | $434M | $443M | $454M | $475M | $484M | $433M | $429M | $418M | · | $390M | $418M | · | $369M | |
| Deferred Tax | $79M | $81M | $95M | $123M | $109M | $107M | $107M | $168M | $165M | $180M | · | $185M | $212M | · | $196M | |
| Other Non-current Liabilities | $403M | $511M | $138M | $189M | $185M | $196M | $195M | $237M | $225M | $235M | · | $173M | $187M | · | $195M | |
| Total Liabilities | $4.64B | $4.74B | $3.92B | $4.06B | $4.16B | $4.34B | $4.02B | $4.18B | $4.18B | $4.45B | · | $4.26B | $4.54B | · | $4.71B | |
| Total Debt | $5M | $7M | · | $54.0K | $98.0K | $121.0K | · | $157.0K | $435.0K | $459.0K | · | $797.0K | · | · | $0 | |
| Common Stock | $496.0K | $493.0K | $492.0K | $514.0K | $513.0K | $512.0K | $511.0K | $517.0K | $517.0K | $515.0K | · | $514.0K | $512.0K | · | $510.0K | |
| Retained Earnings | $1.37B | $1.37B | $1.39B | $1.94B | $1.89B | $1.84B | $1.81B | $2.12B | $2.05B | $1.96B | · | $1.72B | $1.54B | · | $1.28B | |
| Treasury Stock | $323M | $210M | $0 | $363M | $363M | $357M | $0 | $120M | $18M | $9M | · | $24M | $19M | · | $38M | |
| AOCI | $-196M | $-191M | $-172M | $-192M | $-166M | $-265M | $-317M | $-193M | $-270M | $-250M | · | $-268M | $-239M | · | $-396M | |
| Stockholders' Equity | $2.84B | $2.94B | $3.16B | $3.41B | $3.35B | $3.19B | $3.46B | $3.78B | $3.72B | $3.64B | · | $3.31B | $3.11B | · | $2.63B | |
| Liabilities + Equity | $7.53B | $7.73B | $7.14B | $7.51B | $7.56B | $7.58B | $7.53B | $8.00B | $7.95B | $8.15B | · | $7.61B | $7.70B | · | $7.38B | |
| Shares Outstanding | 47,728,000 | 48,167,000 | 49,217,000 | 49,215,000 | 49,209,000 | 49,115,000 | 51,141,000 | 51,134,000 | 51,613,000 | 51,510,000 | · | 51,296,000 | 51,182,000 | 50,944,000 | 50,877,000 |
Flujo de Efectivo 16
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $67M | $67M | $78M | $85M | $120M | $120M | $102M | $88M | $86M | $85M | $81M | $79M | $77M | $78M | $75M | |
| Stock-based Comp | $20M | $22M | $18M | $23M | $17M | $13M | $17M | $19M | $17M | $17M | $20M | $23M | $13M | $22M | $22M | |
| Amort. of Intangibles | $15M | $15M | $21M | $27M | $65M | $65M | $41M | $32M | $32M | $33M | $34M | $34M | $35M | $35M | $36M | |
| Restructuring | $23M | $32M | $26M | $17M | $32M | $24M | $41M | $31M | $18M | $17M | $8M | $15M | $3M | $4M | $1M | |
| Other Non-cash | · | $-34M | · | · | · | $13M | · | · | · | $-45M | · | · | $-84M | · | · | |
| Operating Cash Flow | $180M | $41M | $148M | $214M | $205M | $172M | $159M | $252M | $194M | $130M | $221M | $205M | $109M | $235M | $133M | |
| CapEx | $31M | $56M | $89M | $36M | $35M | $59M | $76M | $39M | $39M | $79M | $78M | $66M | $107M | $89M | $72M | |
| Investing Cash Flow | $28M | $-408M | $-93M | $-34M | $-37M | $-45M | $-76M | $-21M | $-62M | $-86M | $-238M | $-80M | $-169M | $44M | $-92M | |
| Debt Issued | $353M | $912M | $157M | $107M | $547M | $416M | $105M | $236M | $440M | $301M | $443M | $51M | $192M | $154M | $618M | |
| Net Debt Issued | · | $912M | · | · | · | $416M | · | · | · | $301M | · | · | $192M | · | · | |
| Stock Repurchased | $116M | $208M | $96.0K | $93.0K | $7M | $353M | $124.0K | $101M | $9M | $9M | $139.0K | $38.0K | $19M | $159.0K | $24.0K | |
| Net Stock Activity | · | $-208M | · | · | · | $-353M | · | · | · | $-9M | · | · | $-19M | · | · | |
| Financing Cash Flow | $-165M | $348M | $-52M | $-153M | $-227M | $-105M | $-76M | $-208M | $-286M | $18M | $124M | $-163M | $25M | $-249M | $-52M | |
| Net Change in Cash | $42M | $-18M | $7M | $24M | $-47M | $26M | $-6M | $31M | $-158M | $54M | $119M | $-43M | $-32M | $45M | $-11M | |
| Taxes Paid | $16M | $2M | $27M | $19M | $57M | $17M | $31M | $23M | $53M | $19M | $15M | $14M | $14M | · | · | |
| Free Cash Flow | · | $-15M | · | · | · | $112M | · | · | · | $51M | · | · | $3M | · | · |
Rentabilidad 5
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 11.9% | 12.0% | · | 13.3% | 9.7% | 7.6% | · | 11.6% | 14.8% | 12.4% | · | 14.8% | 16.3% | · | 15.3% | |
| Net Margin | -0.15% | -1.5% | · | 5.4% | 5.1% | 2.6% | · | 6.9% | 9.2% | 7.2% | · | 8.5% | 10.0% | · | 9.8% | |
| EBITDA Margin | 18.6% | 18.8% | · | 21.8% | 21.3% | 19.8% | · | 20.4% | 23.2% | 20.9% | · | 22.4% | 23.8% | · | 22.8% | |
| ROA | -0.02% | -0.19% | · | 0.70% | 0.67% | 0.32% | · | 0.89% | 1.2% | 0.92% | · | 1.2% | · | · | 1.3% | |
| ROE | -0.05% | -0.48% | · | 1.5% | 1.5% | 0.75% | · | 2.0% | 2.7% | 2.2% | · | 2.9% | · | · | 3.8% |
Liquidez y Solvencia 4
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.3 | 1.4 | · | 1.4 | 1.4 | 1.4 | · | 1.5 | 1.6 | 1.7 | · | 1.5 | · | · | 1.4 | |
| Quick Ratio | 0.8 | 0.8 | · | 0.8 | 0.9 | 0.9 | · | 1.0 | 1.0 | 1.2 | · | 1.0 | · | · | 1.0 | |
| Debt / Equity | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | · | · | 0.0 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | 3.6 | · | 4.5 | 4.9 | · | 13.3 |
Eficiencia 3
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | · | · | 0.1 | |
| Inventory Turnover | · | · | · | · | · | · | · | 2.1 | 2.1 | 2.1 | · | · | · | · | · | |
| Receivables Turnover | 1.4 | 1.4 | · | 1.4 | 1.3 | 1.3 | · | 1.3 | 1.3 | 1.3 | · | 1.3 | · | · | 1.4 |
Valoración (TTM) 13
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $4.04B | $4.02B | · | $4.03B | $4.05B | $4.03B | · | $4.07B | $4.12B | $4.13B | · | $4.11B | $3.91B | · | $3.77B | |
| Net Income TTM | $90M | $117M | · | $202M | $242M | $262M | · | $324M | $351M | $360M | · | $384M | $402M | · | $402M | |
| Market Cap | $10.30B | $7.67B | · | $7.31B | $7.38B | $7.64B | · | $10.14B | $10.66B | $13.96B | · | $10.05B | · | · | $9.54B | |
| Enterprise Value | $10.11B | $7.48B | · | $7.10B | $7.20B | $7.41B | · | $9.93B | $10.48B | $13.63B | · | $9.90B | · | · | $9.35B | |
| P/E | 117.9 | 67.4 | · | 37.2 | 32.4 | 31.9 | · | 32.7 | 31.2 | 39.3 | · | 26.2 | 25.8 | · | 23.9 | |
| P/S | 2.6 | 1.9 | · | 1.8 | 1.8 | 1.9 | · | 2.5 | 2.6 | 3.4 | · | 2.4 | · | · | 2.5 | |
| P/B | 3.6 | 2.6 | · | 2.1 | 2.2 | 2.4 | · | 2.7 | 2.9 | 3.8 | · | 3.0 | · | · | 3.6 | |
| P / Cash Flow | · | 186.6 | · | · | · | 44.5 | · | · | · | 107.5 | · | · | · | · | · | |
| P / FCF | · | -516.9 | · | · | · | 68.0 | · | · | · | 275.0 | · | · | · | · | · | |
| EV / EBITDA | 54.0 | 40.0 | · | 32.4 | 32.8 | 38.0 | · | 48.3 | 44.1 | 64.5 | · | 43.0 | · | · | 41.4 | |
| EV / FCF | · | -504.4 | · | · | · | 65.9 | · | · | · | 268.6 | · | · | · | · | · | |
| EV / Revenue | 2.5 | 1.9 | · | 1.8 | 1.8 | 1.8 | · | 2.4 | 2.5 | 3.3 | · | 2.4 | · | · | 2.5 | |
| Earnings Yield | 0.85% | 1.5% | · | 2.7% | 3.1% | 3.1% | · | 3.1% | 3.2% | 2.5% | · | 3.8% | 3.9% | · | 4.2% |
Estados Financieros Estado de resultados, balance general, flujo de caja — anual, últimos 5 años
Estado de resultados
| 2025-12-27 | 2024-12-28 | 2023-12-30 | 2022-12-31 | 2021-12-25 | |
|---|---|---|---|---|---|
| Ingresos | $4.02B | $4.05B | $4.13B | $3.98B | $3.54B |
| Margen Operativo % | 0.63% | 5.6% | 14.9% | 16.4% | 16.7% |
| Beneficio neto | $-144M | $22M | $475M | $486M | $391M |
| EPS Diluido | $-2.91 | $0.20 | $9.22 | $9.48 | $7.60 |
Balance general
| 2025-12-27 | 2024-12-28 | 2023-12-30 | 2022-12-31 | 2021-12-25 | |
|---|---|---|---|---|---|
| Deuda / Patrimonio | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Ratio corriente | 1.3 | 1.4 | 1.5 | 1.3 | 1.2 |
| Ratio Rápido | 0.8 | 0.9 | 1.0 | 0.9 | 0.9 |
Flujo de Efectivo
| 2025-12-27 | 2024-12-28 | 2023-12-30 | 2022-12-31 | 2021-12-25 | |
|---|---|---|---|---|---|
| Flujo de caja libre | $518M | $502M | $365M | $295M | $532M |
Últimas noticias Noticias recientes que mencionan a esta empresa
- Bio-Techne toma el puesto #477 de Charles River Laboratories International
- Charles River Laboratories International Llamada de ganancias del primer trimestre Puntos destacados
- Títulos del Tesoro de EE. UU. tokenizados se acercan a los 14 mil millones de dólares a medida que Circle y BlackRock lideran el crecimiento
Mis Métricas Tu lista de seguimiento personal — filas seleccionadas de Fundamentales Completos
📊
Elige las métricas que te importan — haz clic en el ➕ junto a cualquier fila en Fundamentales Completos arriba.
Tu selección se guarda y te sigue en todos los tickers.
Propietarios institucionales (13F) 616 declarantes · $7.8B total · A fecha de 30 de junio de 2026
Instituciones que informan tener esta acción en su Formulario 13F trimestral de la SEC. Solo posiciones largas; un solo presentador puede aparecer dos veces para tramos de opciones separados. Las patas de put/call de compensación grandes suelen reflejar la creación de mercado o el inventario cubierto, no la convicción direccional.
Actividad institucional — Q2 2026 vs trimestre anterior
| Nuevas posiciones | Posiciones cerradas | Aumentado | Disminuido | Cambio neto de acciones |
|---|---|---|---|---|
| 82 (-1 vs trimestre anterior) | 59 (-23 vs trimestre anterior) | 180 (-11 vs trimestre anterior) | 201 (+15 vs trimestre anterior) | +5.0M |
Comparado con Q1 2026. Las presentaciones del Formulario 13F de la SEC vencen dentro de los 45 días posteriores al final del trimestre, más un pequeño margen para los presentadores tardíos; los trimestres que aún se encuentran dentro de esa ventana se omiten en favor del par más reciente completamente reportado.
| Institución | Valor | Acciones | % de 13F rastreadas | Tipo |
|---|---|---|---|---|
| FMR LLC | $737 350 307 | 3 251 247 | 9,42% | Acciones |
| VANGUARD CAPITAL MANAGEMENT LLC | $714 227 026 | 3 149 288 | 9,12% | Acciones |
| HARRIS ASSOCIATES L P | $508 269 048 | 2 241 144 | 6,49% | Acciones |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $501 427 927 | 2 210 979 | 6,40% | Acciones |
| STATE STREET CORP | $422 800 968 | 1 864 284 | 5,40% | Acciones |
| DIMENSIONAL FUND ADVISORS LP | $348 883 077 | 1 538 354 | 4,46% | Acciones |
| CITADEL ADVISORS LLC | $270 696 771 | 1 193 601 | 3,46% | Acciones |
| GEODE CAPITAL MANAGEMENT, LLC | $259 130 041 | 1 144 937 | 3,31% | Acciones |
| EARNEST PARTNERS LLC | $254 007 295 | 1 120 011 | 3,24% | Acciones |
| WELLINGTON MANAGEMENT GROUP LLP | $223 361 616 | 984 883 | 2,85% | Acciones |
| AMERIPRISE FINANCIAL INC | $192 886 814 | 850 503 | 2,46% | Acciones |
| NEUBERGER BERMAN GROUP LLC | $192 182 793 | 847 488 | 2,45% | Acciones |
| Clearbridge Investments, LLC | $177 185 527 | 781 276 | 2,26% | Acciones |
| COOKE & BIELER LP | $171 369 328 | 755 630 | 2,19% | Acciones |
| VICTORY CAPITAL MANAGEMENT INC | $150 762 735 | 664 768 | 1,93% | Acciones |
| MILLENNIUM MANAGEMENT LLC | $110 324 717 | 486 462 | 1,41% | Acciones |
| BANK OF AMERICA CORP /DE/ | $104 921 899 | 462 639 | 1,34% | Acciones |
| Gotham Asset Management, LLC | $98 233 181 | 433 146 | 1,25% | Acciones |
| Amundi | $93 528 650 | 412 402 | 1,19% | Acciones |
| NORGES BANK | $83 921 372 | 370 040 | 1,07% | Acciones |
| MARSHALL WACE, LLP | $76 947 125 | 339 288 | 0,98% | Acciones |
| Iron Triangle Partners LP | $75 748 141 | 379 728 | 0,97% | Acciones |
| ALLIANCEBERNSTEIN L.P. | $64 615 913 | 374 585 | 0,83% | Acciones |
| SNYDER CAPITAL MANAGEMENT L P | $63 899 443 | 281 756 | 0,82% | Acciones |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $63 174 169 | 278 558 | 0,81% | Acciones |
| BNP PARIBAS FINANCIAL MARKETS | $63 095 473 | 278 211 | 0,81% | Acciones |
| VANGUARD FIDUCIARY TRUST CO | $61 384 115 | 270 665 | 0,78% | Acciones |
| PRIMECAP MANAGEMENT CO/CA/ | $60 523 448 | 266 870 | 0,77% | Acciones |
| GOLDMAN SACHS GROUP INC | $57 319 812 | 252 744 | 0,73% | Acciones |
| Meridiem Capital Partners LP | $56 012 367 | 246 979 | 0,72% | Acciones |
| Alyeska Investment Group, L.P. | $53 295 650 | 235 000 | 0,68% | Acciones |
| Quantinno Capital Management LP | $49 020 824 | 216 150 | 0,63% | Acciones |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $48 415 129 | 213 480 | 0,62% | Acciones |
| Boston Trust Walden Corp | $46 506 918 | 205 066 | 0,59% | Acciones |
| Burgundy Asset Management Ltd. | $45 453 909 | 278 329 | 0,58% | Acciones |
| SRS Investment Management, LLC | $42 496 817 | 187 384 | 0,54% | Acciones |
| LOOMIS SAYLES & CO L P | $38 517 487 | 169 838 | 0,49% | Acciones |
| JONES FINANCIAL COMPANIES LLLP | $37 184 513 | 172 350 | 0,47% | Acciones |
| PERCEPTIVE ADVISORS LLC | $31 750 600 | 140 000 | 0,41% | Acciones |
| LAKEWOOD CAPITAL MANAGEMENT, LP | $30 389 860 | 134 000 | 0,39% | Acciones |
| NEW YORK STATE COMMON RETIREMENT FUND | $29 879 583 | 131 750 | 0,38% | Acciones |
| BlackRock, Inc. | $29 025 945 | 127 986 | 0,37% | Acciones |
| PICTON MAHONEY ASSET MANAGEMENT | $26 340 305 | 116 144 | 0,34% | Acciones |
| FIL Ltd | $25 184 576 | 111 048 | 0,32% | Acciones |
| Candriam S.C.A. | $23 824 478 | 105 152 | 0,30% | Acciones |
| Clark Capital Management Group, Inc. | $23 010 567 | 101 462 | 0,29% | Acciones |
| Vanguard Global Advisers, LLC | $22 453 344 | 99 005 | 0,29% | Acciones |
| Swiss National Bank | $22 452 210 | 99 000 | 0,29% | Acciones |
| CONFLUENCE INVESTMENT MANAGEMENT LLC | $20 491 384 | 90 354 | 0,26% | Acciones |
| ENVESTNET ASSET MANAGEMENT INC | $20 280 546 | 89 424 | 0,26% | Acciones |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $19 730 730 | 87 000 | 0,25% | Opción de compra |
| NOMURA HOLDINGS INC | $19 672 672 | 86 744 | 0,25% | Acciones |
| RHUMBLINE ADVISERS | $19 484 825 | 85 916 | 0,25% | Acciones |
| Ilex Capital Partners (UK) LLP | $18 413 760 | 81 193 | 0,24% | Acciones |
| Aristotle Capital Boston, LLC | $18 273 438 | 80 574 | 0,23% | Acciones |
| CITADEL ADVISORS LLC | $17 485 509 | 77 100 | 0,22% | Opción de compra |
| NICHOLAS COMPANY, INC. | $16 305 067 | 71 895 | 0,21% | Acciones |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $15 172 024 | 66 899 | 0,19% | Acciones |
| Mitsubishi UFJ Asset Management Co., Ltd. | $15 164 087 | 66 864 | 0,19% | Acciones |
| Ranger Investment Management, L.P. | $15 009 416 | 66 182 | 0,19% | Acciones |
| California Public Employees Retirement System | $14 670 818 | 64 689 | 0,19% | Acciones |
| Assenagon Asset Management S.A. | $14 020 385 | 61 821 | 0,18% | Acciones |
| ASSETMARK, INC | $13 939 194 | 61 463 | 0,18% | Acciones |
| Rhenman & Partners Asset Management AB | $12 972 388 | 57 200 | 0,17% | Acciones |
| RIVERBRIDGE PARTNERS LLC | $12 859 587 | 56 703 | 0,16% | Acciones |
| TD Asset Management Inc | $12 854 230 | 56 679 | 0,16% | Acciones |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $12 836 314 | 56 600 | 0,16% | Opción de venta |
| Laurus Investment Counsel Inc. | $12 365 663 | 71 685 | 0,16% | Acciones |
| KING LUTHER CAPITAL MANAGEMENT CORP | $12 204 023 | 53 812 | 0,16% | Acciones |
| FRONTIER CAPITAL MANAGEMENT CO LLC | $11 552 133 | 50 938 | 0,15% | Acciones |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $10 732 081 | 47 278 | 0,14% | Acciones |
| RAYMOND JAMES FINANCIAL INC | $10 506 727 | 46 328 | 0,13% | Acciones |
| VANGUARD ASSET MANAGEMENT, Ltd | $10 472 482 | 46 177 | 0,13% | Acciones |
| KENNEDY CAPITAL MANAGEMENT LLC | $9 914 950 | 43 719 | 0,13% | Acciones |
| BARCLAYS PLC | $9 909 816 | 43 696 | 0,13% | Acciones |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $9 827 670 | 56 972 | 0,13% | Acciones |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $9 382 529 | 41 371 | 0,12% | Acciones |
| Park West Asset Management LLC | $9 343 748 | 41 200 | 0,12% | Acciones |
| State of Tennessee, Department of Treasury | $8 457 000 | 37 290 | 0,11% | Acciones |
| J.P. Marvel Investment Advisors, LLC | $8 456 092 | 37 286 | 0,11% | Acciones |
| CASTLEARK MANAGEMENT LLC | $8 174 646 | 36 045 | 0,10% | Acciones |
| JANE STREET GROUP, LLC | $7 869 613 | 34 700 | 0,10% | Opción de compra |
| Pine Ridge Advisers LLC | $7 710 860 | 34 000 | 0,10% | Acciones |
| PRUDENTIAL FINANCIAL INC | $7 346 635 | 32 394 | 0,09% | Acciones |
| Capricorn Fund Managers Ltd | $7 092 630 | 31 274 | 0,09% | Acciones |
| STATE OF WISCONSIN INVESTMENT BOARD | $7 000 554 | 30 868 | 0,09% | Acciones |
| FIRST TRUST ADVISORS LP | $6 951 290 | 30 651 | 0,09% | Acciones |
| Caption Management, LLC | $6 803 700 | 30 000 | 0,09% | Opción de venta |
| Engineers Gate Manager LP | $6 637 463 | 29 267 | 0,08% | Acciones |
| LAWSON KROEKER INVESTMENT MANAGEMENT INC/NE | $6 351 027 | 28 004 | 0,08% | Acciones |
| Midwest Trust Co | $6 091 126 | 26 858 | 0,08% | Acciones |
| VAN ECK ASSOCIATES CORP | $5 942 578 | 26 203 | 0,08% | Acciones |
| SEI INVESTMENTS CO | $5 929 630 | 26 150 | 0,08% | Acciones |
| Sendero Wealth Management, LLC | $5 909 468 | 26 057 | 0,08% | Acciones |
| 13D Management LLC | $5 851 182 | 25 800 | 0,07% | Acciones |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $5 500 853 | 31 889 | 0,07% | Acciones |
| D. E. Shaw & Co., Inc. | $5 462 691 | 24 087 | 0,07% | Acciones |
| INVESTMENT HOUSE LLC | $5 447 042 | 24 018 | 0,07% | Acciones |
| LPL Financial LLC | $5 409 169 | 23 851 | 0,07% | Acciones |
| LRT Capital Management, LLC | $5 348 842 | 23 585 | 0,07% | Acciones |
Informantes de la empresa 57 insiders · 21 directivos · 27 consejeros
| Insider | Rol | Última actividad | Acciones en propiedad | Compras 12m | Ventas 12m | Neto 12m |
|---|---|---|---|---|---|---|
| Glenn Coleman | EVP & Chief Financial Officer | 29 de mayo de 2026 A | 27 752 | 0 | 0 | $0 |
| Flavia Pease | Corporate Executive VP & CFO | 31 de mayo de 2025 F | 17 297 | 0 | 0 | $0 |
| David Ross Smith | Corporate Executive VP & CFO | 3 de marzo de 2022 M | 25 819 | 0 | 0 | $0 |
| Davide Molho | President & COO | 24 de julio de 2018 M | 17 155 | 0 | 0 | $0 |
| Mark Mintz | EVP, Chief Information Officer | 31 de mayo de 2026 F | 9 546 | 0 | 0 | $0 |
| William D Barbo | Corporate Executive VP & CCO | 7 de noviembre de 2024 G | 23 337 | 0 | 0 | $0 |
| John W Kuo | CEVP General Counsel & CCO | 1 de junio de 2020 A | 3 171 | 0 | 0 | $0 |
| David P Johst | Corporate Executive VP | 29 de mayo de 2020 A | 224 478 | 0 | 0 | $0 |
| John J Crowley | SVP, Chief Accounting Officer | 1 de octubre de 2016 F | 5 599 | 0 | 0 | $0 |
| Nancy Gillett | Corporate Executive VP | 2 de marzo de 2016 S | 11 034 | 0 | 0 | $0 |
| Jorg Geller | Corporate Executive VP | 25 de febrero de 2015 M | 14 094 | 0 | 0 | $0 |
| RENAUD REAL H | Corp. Executive VP | 11 de agosto de 2010 F | 74 390 | 0 | 0 | $0 |
| Christopher Berthoux | Executive Vice President | 26 de febrero de 2010 A | 31 897 | 0 | 0 | $0 |
| Joanne P Acford | Corp. Sr VP, GC and Corp. Sec | 11 de agosto de 2007 F | 37 109 | 0 | 0 | $0 |
| David J Elliott | Officer | 29 de junio de 2007 M | 11 750 | 0 | 0 | $0 |
| Cheri L Walker | Corporate Senior VP | 1 de mayo de 2007 A | 6 262 | 0 | 0 | $0 |
| Stephanie B Wells | Senior Vice President | 2 de abril de 2007 A | 11 500 | 0 | 0 | $0 |
| Nicholas Ventresca | Senior Vice President | 2 de abril de 2007 F | 12 713 | 0 | 0 | $0 |
| John C Ho | Senior Vice President | 23 de febrero de 2007 A | 12 710 | 0 | 0 | $0 |
| Brian Bathgate | Corporate Vice President | 27 de febrero de 2006 S | 16 134 | 0 | 0 | $0 |
| Alastair Stuart Mcewan | Corporate VP | 23 de diciembre de 2004 M | 8 000 | 0 | 0 | $0 |
| Steven Barg | Consejero | 2 de junio de 2026 A | 3 287 | 0 | 0 | $0 |
| Nancy C Andrews | Consejero | 12 de mayo de 2026 G | 3 964 | 0 | 0 | $0 |
| Reshema Kemps-Polanco | Consejero | 8 de mayo de 2026 A | 4 563 | 0 | 0 | $0 |
| George Llado | Consejero | 8 de mayo de 2026 A | 6 702 | 0 | 0 | $0 |
| Abraham Ceesay | Consejero | 8 de mayo de 2026 A | 2 384 | 0 | 0 | $0 |
| Mark J Enyedy | Consejero | 8 de mayo de 2026 A | 2 384 | 0 | 0 | $0 |
| Paul W Graves | Consejero | 8 de mayo de 2026 A | 2 384 | 0 | 0 | $0 |
| Craig B. Thompson | Consejero | 8 de mayo de 2026 A | 3 851 | 0 | 0 | $0 |
| Martin Mackay | Consejero | 8 de mayo de 2026 A | 17 137 | 0 | 0 | $0 |
| Virginia M Wilson | Consejero | 8 de mayo de 2026 A | 6 349 | 0 | 0 | $0 |
| George Massaro | Consejero | 15 de mayo de 2025 S | 5 575 | 0 | 0 | $0 |
| Richard F Wallman | Consejero | 7 de noviembre de 2024 S | 0 | 0 | 0 | $0 |
| Deborah Turner Kochevar | Consejero | 13 de mayo de 2024 A | 7 894 | 0 | 0 | $0 |
| Robert J Bertolini | Consejero | 13 de mayo de 2024 A | 32 802 | 0 | 0 | $0 |
| Richard C Reese | Consejero | 15 de mayo de 2023 A | 65 541 | 0 | 0 | $0 |
| George M Milne JR | Consejero | 7 de mayo de 2021 A | 29 079 | 0 | 0 | $0 |
| Stephen D Chubb | Consejero | 23 de febrero de 2021 M | 40 529 | 0 | 0 | $0 |
| Jean-Paul Mangeolle | Consejero | 22 de mayo de 2019 A | 3 886 | 0 | 0 | $0 |
| William Waltrip | Consejero | 5 de diciembre de 2012 S | 21 830 | 0 | 0 | $0 |
| Samuel O Thier MD | Consejero | 9 de mayo de 2012 A | 18 230 | 0 | 0 | $0 |
| Douglas E Rogers | Consejero | 7 de mayo de 2010 A | 12 859 | 0 | 0 | $0 |
| Nancy T Chang | Consejero | 7 de mayo de 2010 A | 31 010 | 0 | 0 | $0 |
| Linda Mcgoldrick | Consejero | 13 de febrero de 2006 A | — | 0 | 0 | $0 |
| Walter S Nimmo | Consejero | 25 de febrero de 2005 S | 149 447 | 0 | 0 | $0 |
| John Urquhart | Consejero | 17 de febrero de 2005 A | 11 738 | 0 | 0 | $0 |
| Louise S Mccrary | Consejero | 17 de febrero de 2005 A | — | 0 | 0 | $0 |
| Robert Cawthorn | Consejero | 2 de junio de 2004 G | 278 600 | 0 | 0 | $0 |
| Shannon M Parisotto | — | 11 de agosto de 2026 M | 4 807 | 0 | 2 | $-2 365 755 |
| Birgit Girshick | — | 11 de agosto de 2026 M | 36 013 | 0 | 1 | $-1 819 350 |
Informantes de las presentaciones SEC Form 3/4/5; neto = solo P/S de mercado abierto
Activistas y propietarios del %+ 5 6 tenencias
Inversores que presentaron el Anexo 13D de la SEC — propiedad beneficiosa superior al % 5 con la intención de influir en el emisor (participaciones activistas, campañas de la junta directiva, M&A). Cada fila muestra el estado conocido más reciente de la posición de ese declarante.
| Declarante | Presentado | Participación | Estado | Propósito | Presentación |
|---|---|---|---|---|---|
| JANA PARTNERS LLC ×4 presentaciones | 4 de agosto de 2011 | — | Presentación inicial | — | SEC |
| Relational Investors, LLC, Relational Investors Mid-Cap Fund I, L.P., Relational Investors Mid-Cap Fund II, L.P., Ralph V. Whitworth, David H. Batchelder, California State Teachers’ Retirement System ×3 presentaciones | 9 de febrero de 2011 | — | Presentación inicial | — | SEC |
| Neuberger Berman Group LLC, Neuberger Berman LLC, Neuberger Berman Management ×3 presentaciones | 7 de diciembre de 2010 | — | Presentación inicial | — | SEC |
| Persona informante no revelada | 16 de junio de 2010 | — | Presentación inicial | — | SEC |
| Persona informante no revelada | 7 de junio de 2010 | — | Presentación inicial | Inversión pasiva | SEC |
| Charles River Laboratories International, Inc. IRS No. 061397316 | 5 de mayo de 2010 | — | Presentación inicial | Campaña de la junta directiva | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Propiedad de ETFs Mantenido por 135 ETFs
El peso refleja solo las tenencias directas de acciones (N-PORT); los fondos apalancados o basados en derivados pueden tener exposición adicional a swaps no mostrada.
| Fondo | Ponderación | Unidades | A fecha de | Fuente |
|---|---|---|---|---|
| RSPH · Invesco Exchange-Traded Fund Trust | 2,18% | 63 652 SH | 8 de agosto de 2026 | Diario |
| HTEC · EXCHANGE TRADED CONCEPTS TRUST | 1,49% | 4 749 NS | 30 de abril de 2026 | N-PORT |
| EPSB · Harbor ETF Trust | 1,33% | 370 NS | 30 de abril de 2026 | N-PORT |
| SPHB · Invesco Exchange-Traded Fund Trust … | 1,18% | 41 597 SH | 8 de agosto de 2026 | Diario |
| EPMV · Harbor ETF Trust | 1,09% | 291 NS | 30 de abril de 2026 | N-PORT |
| IBB · iShares Trust | 0,97% | 349 491 SH | 8 de agosto de 2026 | Diario |
| EPSV · Harbor ETF Trust | 0,90% | 270 NS | 30 de abril de 2026 | N-PORT |
| TAX · EA Series Trust | 0,80% | 1 131 NS | 29 de mayo de 2026 | N-PORT |
| LSEQ · Harbor ETF Trust | 0,66% | 612 NS | 30 de abril de 2026 | N-PORT |
| HIBL · Direxion Shares ETF Trust | 0,50% | 2 356 NS | 30 de abril de 2026 | N-PORT |
| ISCV · iShares Trust | 0,40% | 10 497 SH | 8 de agosto de 2026 | Diario |
| FNY · First Trust Exchange-Traded AlphaDE… | 0,38% | 11 925 NS | 30 de abril de 2026 | N-PORT |
| PKW · Invesco Exchange-Traded Fund Trust | 0,38% | 25 401 SH | 8 de agosto de 2026 | Diario |
| VGHY · VANGUARD FIXED INCOME SECURITIES FU… | 0,36% | 1 145 000 PA | 8 de agosto de 2026 | Diario |
| IQSM · New York Life Investments ETF Trust | 0,33% | 6 161 NS | 30 de abril de 2026 | N-PORT |
| FFSM · FIDELITY COVINGTON TRUST | 0,29% | 22 440 NS | 30 de abril de 2026 | N-PORT |
| RSP · Invesco Exchange-Traded Fund Trust | 0,27% | 996 151 SH | 8 de agosto de 2026 | Diario |
| DFAT · Dimensional ETF Trust | 0,26% | 212 321 NS | 30 de abril de 2026 | N-PORT |
| VBR · VANGUARD INDEX FUNDS | 0,23% | 701 498 SH | 8 de agosto de 2026 | Diario |
| ESML · iShares Trust | 0,23% | 24 979 SH | 8 de agosto de 2026 | Diario |
| BKMC · BNY Mellon ETF Trust | 0,22% | 8 115 NS | 30 de abril de 2026 | N-PORT |
| IYH · iShares Trust | 0,21% | 29 370 SH | 8 de agosto de 2026 | Diario |
| ISCB · iShares Trust | 0,20% | 2 125 SH | 8 de agosto de 2026 | Diario |
| SMMD · iShares Trust | 0,17% | 24 455 SH | 8 de agosto de 2026 | Diario |
| FSMD · FIDELITY COVINGTON TRUST | 0,17% | 24 528 NS | 30 de abril de 2026 | N-PORT |
| SCHM · SCHWAB STRATEGIC TRUST | 0,17% | 133 341 NS | 31 de mayo de 2026 | N-PORT |
| DFAS · Dimensional ETF Trust | 0,16% | 138 243 NS | 30 de abril de 2026 | N-PORT |
| IXJ · iShares Trust | 0,16% | 25 598 SH | 8 de agosto de 2026 | Diario |
| VHT · VANGUARD WORLD FUND | 0,16% | 148 331 SH | 8 de agosto de 2026 | Diario |
| BBMC · J.P. Morgan Exchange-Traded Fund Tr… | 0,15% | 18 369 NS | 30 de abril de 2026 | N-PORT |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0,15% | 6 079 NS | 31 de mayo de 2026 | N-PORT |
| WSML · iShares Trust | 0,13% | 6 018 SH | 8 de agosto de 2026 | Diario |
| FHLC · FIDELITY COVINGTON TRUST | 0,13% | 22 674 NS | 30 de abril de 2026 | N-PORT |
| DFSV · Dimensional ETF Trust | 0,13% | 59 338 NS | 30 de abril de 2026 | N-PORT |
| VB · VANGUARD INDEX FUNDS | 0,13% | 1 102 914 SH | 8 de agosto de 2026 | Diario |
| VGMS · VANGUARD MALVERN FUNDS | 0,13% | 315 000 PA | 8 de agosto de 2026 | Diario |
| EQAL · Invesco Exchange-Traded Fund Trust … | 0,13% | 4 072 SH | 8 de agosto de 2026 | Diario |
| RXL · ProShares Trust | 0,13% | 513 NS | 31 de mayo de 2026 | N-PORT |
| IWS · iShares Trust | 0,13% | 74 284 SH | 8 de agosto de 2026 | Diario |
| REVS · Columbia ETF Trust I | 0,12% | 2 082 NS | 30 de abril de 2026 | N-PORT |
| CURE · Direxion Shares ETF Trust | 0,12% | 982 NS | 30 de abril de 2026 | N-PORT |
| SMLF · iShares Trust | 0,12% | 18 532 SH | 8 de agosto de 2026 | Diario |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,11% | 3 280 NS | 30 de abril de 2026 | N-PORT |
| FBCV · FIDELITY COVINGTON TRUST | 0,11% | 1 032 NS | 30 de abril de 2026 | N-PORT |
| IWR · iShares Trust | 0,09% | 199 595 SH | 8 de agosto de 2026 | Diario |
| AVMC · AMERICAN CENTURY ETF TRUST | 0,09% | 1 986 NS | 31 de mayo de 2026 | N-PORT |
| IEUS · iShares Trust | 0,09% | 4 951 SH | 8 de agosto de 2026 | Diario |
| XOEF · iShares Trust | 0,07% | 61 SH | 8 de agosto de 2026 | Diario |
| VSDB · VANGUARD MALVERN FUNDS | 0,07% | 635 000 PA | 8 de agosto de 2026 | Diario |
| FNX · First Trust Exchange-Traded AlphaDE… | 0,07% | 5 261 NS | 30 de abril de 2026 | N-PORT |